Aviptadil by Relief Therapeutics for Respiratory Tract Inflammatory Disorders: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aviptadil overview
Aviptadil is under development for the treatment of pulmonary sarcoidosis, coronavirus disease 2019 (COVID-19) pneumonia, checkpoint inhibitor-induced pneumonitis, chronic berylliosis, non-acute lung injury in coronavirus disease (COVID-19), coronavirus disease (COVID-19) associated acute lung injury, coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome and Infectious acute respiratory distress syndrome (ARDS) (non-COVID-19-related). The drug candidate is administered through inhalation and intravenous route. Aviptadil is a synthetic analogue of 28 amino acid vasoactive intestinal polypeptide. It acts by targeting VIP receptors Vasoactive Intestinal Polypeptide Receptor 1 and Vasoactive Intestinal Polypeptide Receptor 2. It was also under development for the treatment of idiopathic pulmonary fibrosis, acute lung injury and pulmonary arterial hypertension.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Relief Therapeutics overview
Relief Therapeutics is a drug development company that offers clinical development of peptides and proteins of natural or engineered origin. Its pipeline drug candidates include PKU GOLIKE, ACER-001, APR-OD032, RLF-100, APR-TD011 and APR-TM011. The company offer its products in the therapeutic areas of rare metabolic disorders, rare pulmonary diseases, and rare connective tissue disorders, with particular emphasis on conditions with dermatological manifestations. It partners with academic institutions, healthcare researchers and patient support groups for product development and commercialization. Relief Therapeutics is headquartered in Geneve, Switzerland.
For a complete picture of Aviptadil’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#Aviptadil #Relief #Therapeutics #Respiratory #Tract #Inflammatory #Disorders #Likelihood #Approval
